{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:44:19Z","timestamp":1786617859772,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017209","name":"Fundaci\u00c3\u00b3n Instituto de Investigaci\u00c3\u00b3n Sanitaria de Santiago de Compostela","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metabolic decompensation episodes (DEs) in Maple Syrup urine disease (MSUD) result in brain accumulation of toxic branched-chain amino acids (BCAAs) and their respective branched-chain \u03b1-keto acids that could induce neuroinflammation, disturb brain bioenergetics, and alter glutamate and glutamine synthesis. These episodes require immediate intervention to prevent irreversible neurological damage. Intravenous (IV) administration of BCAA-free solution could represent a powerful alternative for emergency treatment of decompensations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This pediatric series discusses the management of DEs in MSUD patients with IV BCAA-free solution, as an emergency treatment for DEs or as a prophylactic in cases requiring surgery. Clinical evolution, amino acid profile and adverse effects were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We evaluated the use of BCAA-free solution in 5 DEs in 5 MSUD pediatric patients, all with significantly elevated plasma leucine levels at admission (699\u20133296 \u03bcmol\/L) and in 1 episode of risk of DE due to surgery. Leucine normalization was achieved in all cases with resolution or improvement of clinical symptoms following IV BCAA-free solution. The duration of administration ranged from 3\u201320 days. Administration of IV BCAA-free solution at the beginning of a DE could reverse depletion of the amino acids that compete with BCAAs for the LAT1 transporter, and the observed depletion of alanine, despite IV alanine supplementation. No related adverse events were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Administration of standardized IV BCAA-free solution in emergency settings constitutes an important and safe alternative for the treatment of DEs in MSUD, especially in pediatric patients for whom oral or enteral treatment is not viable.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.969741","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:54:45Z","timestamp":1660539285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Paula","family":"S\u00e1nchez-Pintos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Meavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Goretti","family":"L\u00f3pez-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Garc\u00eda-Cazorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Couce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105360","DOI":"10.1016\/j.neuint.2022.105360","article-title":"Pathophysiology of maple syrup urine disease: focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain \u03b1-keto acids","volume":"157","author":"Amaral","year":"2022","journal-title":"Neurochem Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.brainres.2010.02.018","article-title":"Alpha-ketoisocaproic acid and leucine provoke mitochondrial bioenergetic dysfunction in rat brain","volume":"1324","author":"Amaral","year":"2010","journal-title":"Brain Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijdevneu.2019.07.007","article-title":"Administration of branched-chain amino acids increases the susceptibility to lipopolysaccharide-induced inflammation in young Wistar rats","volume":"78","author":"Wessler","year":"2019","journal-title":"Int J Dev Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1531s","DOI":"10.1093\/jn\/135.6.1531S","article-title":"Brain amino acid requirements and toxicity: the example of leucine","volume":"135","author":"Yudkoff","year":"2005","journal-title":"J Nutr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ymgme.2020.01.006","article-title":"Branched-Chain ?","volume":"129","author":"Strauss","year":"2020","journal-title":"Mol Genet Metab."},{"key":"B6","author":"Strauss","year":"2006","journal-title":"Maple Syrup Urine Disease"},{"key":"B7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ymgme.2014.05.006","article-title":"Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach","volume":"112","author":"Frazier","year":"2014","journal-title":"Mol Genet Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/tacg.S125962","article-title":"Maple syrup urine disease: mechanisms and management","volume":"10","author":"Blackburn","year":"2017","journal-title":"Appl Clin Genet."},{"key":"B9","volume-title":"Maple Syrup Urine Disease.","author":"Hassan","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10238-016-0435-0","article-title":"Classical organic acidurias: diagnosis and pathogenesis","volume":"17","author":"Villani","year":"2017","journal-title":"Clin Exp Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.3390\/ijms21207490","article-title":"Brain branched-chain amino acids in maple syrup urine disease: implications for neurological disorders","volume":"21","author":"Xu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00467-021-05329-9","article-title":"Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders","volume":"37","author":"Eminoglu","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/PEC.0000000000001299","article-title":"Acute illness protocol for maple syrup urine disease","volume":"1","author":"Rodan","year":"2018","journal-title":"Pediatr Emerg Care."},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1542\/peds.92.2.280","article-title":"Nasogastric drip feeding as the only treatment of neonatal maple syrup urine disease","author":"Parini","year":"1993","journal-title":"Pediatrics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1023\/a:1005324516186","article-title":"Maple Syrup urine disease: nutritional management by intravenous hyperalimentation and uneventful course after surgical repair of dislocation of the hip","volume":"21","author":"Koga","year":"1998","journal-title":"J Inherit Metab Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1046\/j.1442-200x.1999.4121044.x","article-title":"Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study","volume":"41","author":"Yoshino","year":"1999","journal-title":"Pediatr Int."},{"key":"B17","first-page":"6","volume-title":"Protocolos de Diagn\u00f3stico y Tratamiento de los Errores Cong\u00e9nitos del Metabolismo","author":"Gil Ortega","year":"2018"},{"key":"B18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/ajcn\/36.2.359","article-title":"Total parenteral nutrition therapy of toxic maple syrup urine disease","volume":"36","author":"Townsend","year":"1982","journal-title":"Am J Clin Nutr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/s0022-3476(05)82198-5","article-title":"Continuous venovenous hemofiltration in the management of acute decompensation in inborn errors of metabolism","volume":"118","author":"Thompson","year":"1991","journal-title":"J Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1056\/nejm199101173240307","article-title":"Branched-chain amino acid-free parenteral nutrition in the treatment of acute metabolic decompensation in patients with maple syrup urine disease","volume":"324","author":"Berry","year":"1991","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1542\/peds.109.6.999","article-title":"Diagnosis and treatment of maple syrup disease: a study of 36 patients","volume":"109","author":"Morton","year":"2002","journal-title":"Pediatrics."},{"key":"B22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jmd2.12207","article-title":"Real-World Management of Maple Syrup Urine Disease (Msud) metabolic decompensations with branched chain amino acid-free formulas in france and germany: a retrospective observational study","volume":"59","author":"de Lonlay","year":"2021","journal-title":"JIMD Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10545-012-9570-2","article-title":"Treatment of acute decompensation of maple syrup urine disease in adult patients with a new parenteral amino-acid mixture","volume":"36","author":"Servais","year":"2013","journal-title":"J Inherit Metab Dis."},{"key":"B24","article-title":"Intravenous administration of a specific amino-acid mixture in children and adults with acute decompensation of maple syrup urine disease: a prospective observational study","volume":"38","author":"Alili","year":"2015","journal-title":"J Inherit Metab Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10545-017-0083-x","article-title":"Long-Term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease","volume":"40","author":"Abi-Ward\u00e9","year":"2017","journal-title":"J Inherit Metab Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s1695-4033(07)70651-3","article-title":"Juan JA, Fraga Berm\u00fadez JM. Advances in the diagnosis and treatment of maple syrup urine disease: experience in galicia (Spain)","volume":"67","author":"Couce Pico","year":"2007","journal-title":"An Pediatr (Barc)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000106102","article-title":"High-Volume continuous venovenous hemofiltration as an effective therapy for acute management of inborn errors of metabolism in young children","volume":"25","author":"Lai","year":"2007","journal-title":"Blood Purif."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1007\/s00134-001-1124-2","article-title":"Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease","volume":"27","author":"Jouvet","year":"2001","journal-title":"Intensive Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00467-001-0801-2","article-title":"utility of hemodialysis in maple syrup urine disease","volume":"17","author":"Puliyanda","year":"2002","journal-title":"Pediatr Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/01.pcc.0000113265.92664.91","article-title":"Amino acid clearance during acute metabolic decompensation in maple syrup urine disease treated with continuous venovenous hemodialysis with filtration","volume":"5","author":"Hmiel","year":"2004","journal-title":"Pediatr Crit Care Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1055\/s-0030-1247508","article-title":"Continuous venovenous hemofiltration rapidly lowers toxic metabolites in a patient with msud and imminent cerebral herniation","volume":"222","author":"Thimm","year":"2010","journal-title":"Klin Padiatr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymgmr.2015.07.001","article-title":"Haemodialysis is an effective treatment in acute metabolic decompensation of maple syrup urine disease","volume":"4","author":"Atwal","year":"2015","journal-title":"Mol Genet Metab Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000443783","article-title":"Continuous venovenous hemodiafiltration in the treatment of maple syrup urine disease","volume":"42","author":"Demirkol","year":"2016","journal-title":"Blood Purif."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.ymgmr.2020.100655","article-title":"Enteral tube feeding in patients receiving dietary treatment for metabolic diseases: a retrospective analysis in a large French Cohort","volume":"26","author":"B\u00e9rat","year":"2021","journal-title":"Mol Genet Metab Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13023-022-02353-2","article-title":"Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study","volume":"17","author":"Alili","year":"2022","journal-title":"Orphanet J Rare Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1515\/jpem-2020-0356","article-title":"Impact of sodium phenylbutyrate treatment in acute management of maple syrup urine disease attacks: a single-center experience","volume":"34","author":"Zubarioglu","year":"2021","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100685","DOI":"10.1016\/j.ymgmr.2020.100685","article-title":"Growth hormone as a rescue treatment in maple syrup urine disease with lessons from pediatric burn literature, case report and brief literature review","volume":"25","author":"Kimbrell","year":"2020","journal-title":"Mol Genet Metab Rep."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.969741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:54:54Z","timestamp":1660539294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.969741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":37,"alternative-id":["10.3389\/fped.2022.969741"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.969741","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"article-number":"969741"}}